MIM
SAGE

Monashee Investment Management’s Sage Therapeutics SAGE Stock Holding History

Monashee Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Hold
0
– – – 42
2018
Q2 		– Sell
-110,000
Closed -$17.3M – 26
2018
Q1 		$17.7M Buy
+110,000
New +$18.7M 4.89% 1
2017
Q4 		– Hold
0
– – – 5
2016
Q3 		– Hold
0
– – – 38

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Monashee Investment Management's SAGE Position: Q3 2018 in Review

Monashee Investment Management held its Sage Therapeutics (SAGE) position steady in Q3 2018 at 0 shares worth $2.83M. The position accounts for 0.6% of the portfolio, ranked #42.

Monashee Investment Management first reported a position in SAGE in Q1 2018 and has held it in 1 quarter since. The position peaked at $17.7M in Q1 2018. 275 funds tracked by Wall St. Rank hold SAGE as of Q3 2018.

  • Monashee Investment Management held 0 shares of Sage Therapeutics worth $2.83M as of Q3 2018.
  • Monashee Investment Management left its Sage Therapeutics share count unchanged in Q3 2018.
  • Sage Therapeutics made up 0.6% of Monashee Investment Management's portfolio in Q3 2018, its #42 holding.
  • Monashee Investment Management first reported a position in Sage Therapeutics in Q1 2018 and has held it in 1 quarter since.
  • Monashee Investment Management's Sage Therapeutics position peaked at $17.7M in Q1 2018.
  • 275 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2018.

Based on Monashee Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.